At Sola Dx, we are revolutionising personalised primary and secondary prevention through ground-breaking innovations, including the WID®-easy Test for the early detection of endometrial cancer and the WID®-can Test for cervical cancer risk prediction.

Our key focus is driving the rapid adoption of the WID®-easy Test among symptomatic women in major global markets, laying the groundwork for population-wide screening and unlocking substantial market potential.

The WID®-can Test is poised to redefine cervical cancer screening as a non-cytology molecular triage tool. Unlike traditional methods reliant on cellular morphology, the WID®-can Test can be performed on self-collected samples, offering superior objectivity, reproducibility, and accessibility compared to current standards.

The WID®-ok Test is designed to identify women at high risk for ovarian cancer, regardless of genetic predisposition. By detecting risk factors beyond hereditary mutations, the WID®-ok Test enables proactive prevention, offering a crucial opportunity to intervene before this highly lethal disease develops.

The WID®-best Test represents a breakthrough in breast cancer risk stratification by leveraging an epigenetic signature detected in cervical smear samples. This cutting-edge test identifies women at heightened risk of developing breast cancer, enabling personalized primary prevention strategies and facilitating risk-adjusted screening protocols.

Through our unwavering commitment to innovation, we are addressing the critical diagnostic needs of women today while paving the way for a future where personalized, accessible, and effective cancer prevention becomes the global Standard Of Care.

At Sola Dx, we are a commercial-stage epigenetic diagnostics company built on over 30 years of ground-breaking research in DNA methylation and gynaecological cancers. Our technologies originate from the pioneering work of Prof. Martin Widschwendter and his world-renowned academic team. Leveraging cutting-edge epigenetic science, we develop diagnostic tests that are both highly accurate and minimally invasive. By focusing on tailored precision prevention, we empower women with the knowledge and tools to make better informed health decisions, setting us apart as leaders in women’s health diagnostics.

• Patient-Focussed: We prioritize the well-being and needs of women, ensuring our diagnostic solutions are accessible, minimally invasive, and designed to improve patient outcomes.
• Scientific Excellence: Our work is grounded in over 30 years of pioneering research in DNA methylation and women’s cancers, led by Prof. Martin Widschwendter.
• Innovation: We leverage cutting-edge epigenetic research to develop advanced precision prevention tests that are both highly accurate and minimally invasive.
• Integrity: We uphold the highest ethical standards in our research, partnerships, and operations.
• Collaboration: We work with global partners to expand access and improve outcomes in women’s health diagnostics.
• Empowerment: We provide women with the knowledge and tools to take charge of their health and well-being.

• WID®-easy Test launched in Austria and Switzerland
• WID®-can Test’s performance published in Nature Medicine
• WID®-easy Test UKCA-marked

• WID®-easy Test launched in the UK
• NHS Service Evaluation programme initiated across NHS sites in England
• NIHR i4i grant (£2.16 million) secured to fund the EASY-CARE study
• Seed financing round of €1 million closed

• WID®-easy Test launched in Germany
• WID®-easy Test referenced in the German S3 Guideline on Endometrial Cancer (v4.0)
• Health-economic evidence published (Snowsill 2026, Value in Health)